Существующие проблемы профилактики и лечения химиоиндуцированной периферической нейропатии: мировой опыт и собственные данные

Химиоиндуцированная периферическая нейропатия (ХИПН) — осложнение, которое возникает у большинства пациентов при проведении противоопухолевой терапии с применением таксанов и препаратов платины. ХИПН включает в себя широкую палитру клинических проявлений. наиболее частыми из которых выступают нарушения чувствительности. У части пациентов проявления ХИПН сохраняются даже после завершения химиотерапии. Влияние на качество жизни, высокая распространенность ХИПН среди онкологических пациентов, делает актуальным поиск новых методов медикаментозной коррекции данного осложнения. В данном обзоре обсуждаются существующие проблемы в отношении медикаментозной профилактики и лечения ХИПН. Нами также представлен собственный опыт наблюдения за пациентами с химиоиндуцированной нейропатией. Опираясь на результаты наших наблюдений за пациентами, показано влияние данного осложнения на качество жизни пациентов, выходящее за рамки нарушения периферической сенсорной чувствительности. Это следует учитывать при дальнейшем изучении возможности медикаментозной коррекции данного нежелательного явления.

1. William J.G., Meena S.M., Jame A., et al. NCCN Guidelines insights: breast cancer, version 4.2023. J Natl Compr Canc Netw 2023;21(6):594–608. https://doi.org/10.6004/jnccn.2023.0031

2. Ettinger D.S., Wood D.E., Aisner D.L., et al. Non-Small Cell Lung Cancer. NCCN Guidelines Version 3.2023. J Natl Compr Canc Netw 2023;21(4):340–350. https://doi.org/10.6004/jnccn.2023.0020

3. NCCN Guidelines, Version 3.2023. Small Cell Lung Cancer. Available at: https://www.nccn.org/guidelines/nccn-guidelines/guidelines-detail?category =1&id =1462

4. NCCN Guidelines, Version 2.2023. Colon Cancer. Available at: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf

5. NCCN Guidelines, Version 2.2023. Prostate Cancer. Available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf

6. Seretny M., Currie G.L., Sena E.S., et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 2014;155(12):2461–2470. https://doi.org/10.1016/j.pain.2014.09.020

7. Staff N.P., Grisold A., Grisold W., Windebank A.J. Chemotherapy-induced peripheral neuropathy: A current review. Ann Neurol 2017;81(6):772–781. https://doi.org/10.1002/ana.24951

8. Hausheer F.H., Schilsky R.L., Bain S., et al. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 2006;33(1):15–49. https://doi.org/10.1053/j.seminoncol.2005.12.010

9. Park S.B., Lin C.S., Krishnan A.V., et al. Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist 2011;16(5):708–16. https://doi.org/10.1634/theoncologist.2010-0248

10. Molassiotis A., Cheng H.L., Leung K.T., et al. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. Brain Behav 2019;9(6):e01312. https://doi.org/10.1002/brb3.1312

11. Kalfakis N., Panas M., Karadima G., et al. Hereditary neuropathy with liability to pressure palsies emerging during vincristine treatment. Neurology 2002;59(9):1470–1. https://doi.org/10.1212/01.wnl.0000032505.45389.94

12. Chaudhry V., Chaudhry M., Crawford T.O., et al. Toxic neuropathy in patients with pre-existing neuropathy. Neurology 2003;60(2):337–40. https://doi.org/10.1212/01.wnl.0000043691.53710.53

13. Chauvenet A.R., Shashi V., Selsky C., et al. Vincristine-induced neuropathy as the initial presentation of charcot-marie-tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Pediatr Hematol Oncol 2003;25(4):316–20. https://doi.org/10.1097/00043426-200304000-00010

14. Gu J., Lu H., Chen C., et al. Diabetes mellitus as a risk factor for chemotherapy-induced peripheral neuropathy: a meta-analysis. Support Care Cancer 2021;29(12):7461–7469. https://doi.org/10.1007/s00520-021-06321-7

15. Molassiotis A., Cheng H.L., Leung K.T., et al. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. Brain Behav 2019;9(6):e01312. https://doi.org/10.1002/brb3.1312

16. McWhinney-Glass S., Winham S.J., Hertz D.L., et al. Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity. Clin Cancer Res 2013$19(20):5769–5776. https://doi.org/10.1158/1078-0432.CCR-13-0774

17. Jennaro T.S., Fang F., Kidwell K.M., et al. Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathy. Breast Cancer Res Treat 2020;180(3):707–714. https://doi.org/10.1007/s10549-020-05584-8

18. Hershman D.L., Till C., Wright J.D., et al. Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials. J Clin Oncol 2016;34(25):3014–22. https://doi.org/10.1200/JCO.2015.66.2346

19. Solomon L.R. Functional vitamin B12 deficiency in advanced malignancy: implications for the management of neuropathy and neuropathic pain. Support Care Cancer 2016;24(8):3489–94. https://doi.org/10.1007/s00520-016-3175-5

20. EL-Najjar S.E., Naser I.A., AL-Wahidi K.M. Is Functional Vitamin B12 Deficiency a Risk Factor for the Development of Chemotherapy-Induced Peripheral Neuropathy in Cancer Patients? Research Square 2022. https://doi.org/10.21203/rs.3.rs-1667065/v2

21. Starobova H., Vetter I. Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy. Front Mol Neurosci 2017;10:174. https://doi.org/10.3389/fnmol.2017.00174

22. Lee J.J., Swain S.M. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 2006;24(10):1633–42. https://doi.org/10.1200/JCO.2005.04.0543

23. de Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18(16):2938–47. https://doi.org/10.1200/JCO.2000.18.16.2938

24. Park S.B., Goldstein D., Krishnan A.V., et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin 2013;63(6):419–37. https://doi.org/10.3322/caac.21204. PMID: 2459086

25. Loprinzi C.L., Lacchetti C., Bleeker J., et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol 2020;38(28):3325–3348. https://doi.org/10.1200/JCO.20.01399

26. Jordan B., Margulies A., Cardoso F., et al. Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol 2020;31(10):1306–1319. https://doi.org/10.1016/j.annonc.2020.07.003

27. Avallone A., Bimonte S., Cardone C., et al. Pathophysiology and Therapeutic Perspectives for Chemotherapy-induced Peripheral Neuropathy. Anticancer Res 2022;42(10):4667–4678. https://doi.org/10.21873/anticanres.15971

28. Akin E.J., Alsaloum M., Higerd G.P., et al. Paclitaxel increases axonal localization and vesicular trafficking of Nav1.7. Brain 2021;144(6):1727–1737. https://doi.org/10.1093/brain/awab113

29. Krukowski K., Ma J., Golonzhka O., et al. HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy. Pain 2017;158(6):1126–1137. https://doi.org/10.1097/j.pain.0000000000000893

30. Zheng H., Xiao W.H., Bennett G.J. Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy. Exp Neurol 2011;232(2):154–61. https://doi.org/10.1016/j.expneurol.2011.08.016

31. Fumagalli G., Monza L., Cavaletti G., et al. Neuroinflammatory Process Involved in Different Preclinical Models of Chemotherapy-Induced Peripheral Neuropathy. Front Immunol 2021:11:626687. https://doi.org/10.3389/fimmu.2020.626687

32. Smith E.M., Pang H., Cirrincione C., et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 2013;309(13):1359–1367. https://doi.org/10.1001/jama.2013.2813

33. Farshchian N., Alavi A., Heydarheydari S., et al. Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy. Cancer Chemother Pharmacol 2018;82:787–793. https://doi.org/10.1007/s00280-018-3664-y

34. Matsuoka H., Clark K., Fazekas B., et al. Phase III, international, multicentre, double-blind, dose increment, parallel-arm, randomised controlled trial of duloxetine versus pregabalin for opioid-unresponsive neuropathic cancer pain: a JORTC-PAL16 trial protocol. BMJ Open 2022;12(2):e050182. https://doi.org/10.1136/bmjopen-2021-050182

35. Hershman D.L., Unger J.M., Crew K.D., et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol 2013;31(20):2627–33. https://doi.org/10.1200/JCO.2012.44.8738

36. Kautio A.L., Haanpää M., Saarto T., Kalso E. Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manage 2008;35(1):31–9. https://doi.org/10.1016/j.jpainsymman.2007.02.043

37. Gedlicka C., Scheithauer W., Schüll B., Kornek G.V. Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid. J Clin Oncol 2002;20(15):3359–61. https://doi.org/10.1200/JCO.2002.99.502

38. Guo Y., Jones D., Palmer J.L., et al. Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial. Support Care Cancer 2014;22(5):1223–31. https://doi.org/10.1007/s00520-013-2075-1

39. Dinicola S., Fuso A., Cucina A., et al. Natural products - alpha-lipoic acid and acetyl-L-carnitine - in the treatment of chemotherapy-induced peripheral neuropathy. Eur Rev Med Pharmacol Sci 2018;22(14):4739–4754. https://doi.org/10.26355/eurrev_201807_15534.2018

40. Mitchell P.L., Goldstein D., Michael M., et al. Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity. Clin Colorectal Cancer 2006;6(2):146–51. https://doi.org/10.3816/CCC.2006.n.032